J&J Intermediary Drug Rule Case Won't Get 2nd Look

Law360, New York (August 17, 2012, 4:48 PM EDT) -- The Texas Supreme Court on Friday said it won't revisit a June ruling in which it reversed a $3.8 million award against a Johnson & Johnson unit and ruled for the fist time that prescription drugs fall under the so-called learned intermediary doctrine.

The high court denied a motion for rehearing from plaintiff Patricia Hamilton, who claimed she suffered from a lupuslike syndrome allegedly caused by Remicade, a rheumatoid arthritis and Crohn's disease treatment made by Centocor Inc. A Centocor video that Hamilton viewed during the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.